WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, has entered into definitive agreements for the purchase and sale of 2,900,000 shares of LIXTE’s common stock at a purchase price of $2.00 per share in a registered direct offering.